<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016573</url>
  </required_header>
  <id_info>
    <org_study_id>070/12</org_study_id>
    <secondary_id>1034397</secondary_id>
    <nct_id>NCT02016573</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Uncontrolled Hypertension</brief_title>
  <acronym>RDNP-2012-02</acronym>
  <official_title>Renal Denervation for Uncontrolled Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study investigating the safety and usefulness of the Renal Denervation Procedure
      in reducing high blood pressure in people whose blood pressure is not adequatley controlled
      despite already being treated with 2 blood pressure lowering drugs. This study is designed
      to compare the effects renal denervation to a usual care group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 4 randomised control trial of renal denervation for the treatment of
      uncontrolled hypertension.

      Previous studies have shown that the renal denervation procedure is safe and effective in
      reducing blood pressure.

      A total of 100 participants with uncontrolled blood pressure, treated with two blood
      pressure lowering medications will be recruited into the study. Patients will be assigned to
      one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation
      procedure. Participants in group 2 will undergo usual care, receiving additional
      antihypertensive medication in an attempt to reach blood pressure targets.

      The duration of this study is 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>blood pressure control</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>percentage of patients who achieve BP target at 6 months post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of drugs required to reach target blood pressure</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of drugs required to reach target blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achieve blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to achieve blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in sympathetic nerve activity</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>changes in muscle sympathetic nerve activity (MSNA), renal and whole body NE spillover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular structure and function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in left Ventricular mass index, ejection fraction, diastolic filling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Quality of life as assessed be relevant questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum and Urine Biochemistry</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma Renin Activity, aldosterone levels, eGFR, UACR, inflammatory markers, 24 hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, C-peptide, HOMA index, Lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markes of arterial stiffness</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in markers of arterial stiffness as assessed by AI and PWV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants randomised to undergo the renal denervation procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal Denervation Catheter</description>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <other_name>Symplicity Renal Denervation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BP ≥140/90mmHg (or ≥130/80mmHg for patients with diabetes)

          -  concurrent treatment with 2 anti-hypertensive drugs

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using MDRD calculation)

          -  individual has had myocardial infarction, unstable angina or cerebrovascular accident
             within 6 months of screening visit

          -  female participants of child bearing potential must have negative pregnancy test
             prior to treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus P Schlaich, MD</last_name>
    <phone>+61 3 8352 1502</phone>
    <email>markus.schlaich@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Marusic, B.App.Sci.</last_name>
    <phone>+61 3 8532 1734</phone>
    <email>petra.marusic@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred &amp; Baker Medical Unit</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus P Schlaich, MD</last_name>
      <phone>+61 3 8532 1502</phone>
      <email>markus.schlaich@bakeridi.edu.au</email>
    </contact>
    <investigator>
      <last_name>Markus P Schlaich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>target organ damage</keyword>
  <keyword>sympathetic activity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
